Picture of Vitrolife AB logo

VITR — Vitrolife AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

Spanish fertility firm IVI-RMA attracts buyout bids worth $2.2 billion -sources

By Andres Gonzalez
    MADRID, Jan 31 (Reuters) - Buyout funds including KKR
 KKR.N  and Permira are lining up preliminary bids worth up to 2
billion euros ($2.24 billion) for Spain's IVI-RMA, sources told
Reuters, amid growing demand for companies offering fertility
treatment in Europe.
    Fertility companies are attracting growing interest from
private equity and other buyers as both the number of couples
with fertility problems and the age of first time mothers rises.
    Bain Capital, CVC Capital Partners, Carlyle and PAI Partners
are also looking to submit offers for a controlling stake in the
Spanish group ahead of a deadline for non-binding offers in late
February, the sources said on condition of anonymity.
    Valencia-based IVI-RMA, KKR, Carlyle, Permira and PAI
declined to comment. Bain Capital and CVC were not immediately
available to comment. 
    Spain is one of Europe's largest markets for in-vitro
fertilization (IVF) and is expected to be the main contributor
to the region's overall IVF revenues, with a compound average
growth rate (CAGR) of 7.21% due to an increase in fertility
tourism and the high success rates of treatments, a study by
Market Data Forecast said.
    IVI-RMA was formed in 2017 when a group of doctors and
investors from Spain's eastern region of Valencia merged IVI
with U.S. rival RMANJ. IVI's investors control 70% of the
combined entity, while RMANJ has the balance.
    The firm, which manages more than 75 clinics and 28 labs in
nine countries, could be valued at between 16 and 17 times its
core earnings of 120 million euros, one of the sources said.
    The World Health Organization (WHO) estimates that 15% of
reproductive-aged couples worldwide are affected by infertility,
while Eurostat found that the average age of women giving birth
to their first child in the EU was 29.4 years in 2019.
    With plentiful cash available, private equity firms have
moved to invest in the sector, with KKR buying GeneraLife, one
of Europe's largest fertility clinic groups, in November.
    EQT, meanwhile, sold its reproductive genetic testing
services provider Igenomix to Swedish medical technology group
Vitrolife in a deal worth 1.25 billion euros.
($1 = 0.8949 euros)  

 (Reporting by Andres Gonzalez, editing by Pamela Barbaglia and
Alexander Smith)
 ((andres.gonzalez@thomsonreuters.com; 0034 647 69 49 89;
Reuters Messaging:
andres.gonzalez.thomsonreuters.com@reuters.net))

Recent news on Vitrolife AB

See all news